Breast Cancer

Women whose tumors responded to estrogen treatment were found to benefit from hormone therapy, whereas those whose tumors did not respond experienced worsening disease.

The guidelines recommend discontinuing routine mammograms for survivors with a life expectancy under 5 years, considering stopping screening for those with a 5- to 10-year life expectancy, and continuing mammography for those whose life expectancy is greater than 10 years.

Research highlights the need for cardiologists and cardio-oncologists to be involved in the treatment of men with breast cancer due to common risk factors and potential cardiotoxic effects of treatment.

During a study investigating therapeutics that target how RNA splicing activates antiviral immune pathways in triple-negative breast cancers, researchers observed that endogenous RNA in tumor cells that had been mis-spliced is able to mimic an RNA virus.

Obstacles to cancer screenings for low-income patients can include lack of transportation and an inability to take time off of work.

Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.

According to the study authors, previous small studies suggested that women taking statins may have less heart muscle damage from these types of chemotherapy, yet the exact mechanisms of how statins protect against the cardiac cell damage remains unknown.

This study points to the potential for using CAR T-cell therapy effectively against solid tumors, as well, according to the authors.

Targeting screening to high-risk groups who are less compliant with recommendations could be more effective than general age-based recommendations.

Updated phase 3 progression-free survival and overall survival data demonstrated clinical benefits in efficacy and tolerability of oral paclitaxel and encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Financial toxicity can lead to worse long-term outcomes and psychological distress among patients with breast cancer.

Study shows the mortality rate among breast cancer survivors is lower among those who received fertility preservation.

Although postoperative radiation therapy affected the risk of local recurrence of breast cancer, it did not significantly impact certain other clinical outcomes, including distant metastasis and recurrence in the opposite breast.

The higher risk of delivery and fetal complications suggests that physicians should more closely monitor pregnant breast cancer survivors.

Session at at the San Antonio Breast Cancer Symposium featured several abstract presentations on disparities in health care access in breast cancer, including research on the necessity of avoiding a one-size-fits-all approach to medicine.

Younger and Black patients are more likely to experience breast cancer symptom under-recognition.

Overdiagnosis of breast cancer can lead to unnecessarily aggressive treatments and mastectomies.

There were significant modifications in breast cancer treatment due to the coronavirus disease 2019 pandemic, such as high rates of NET chemotherapy, genomic assay testing on core biopsies, and delays in planned surgeries.

Study indicates pure CBD was able to reduce cell viability in 3 of the 6 cell lines and that this effect was cell line specific rather than specific to certain cancers.

Medicaid expansion was associated with a 2% drop in cancer mortality, a recent study found.

The new optical sensing method is based on multi-pass spectroscopy and can detect the presence of 1 molecule of formaldehyde in a million air particles, or 1 part per million, even in the presence of gasses that often interfere with optical measurements.

Pharmacists can play an integral role in educating patients with breast cancer to improve health outcomes.

Researchers hope clinical trials will begin soon to evaluate oral LMTK3 inhibitors across cancer types.

PD-L1 IHC 22C3 pharmDx will aid in the identification of patients with triple-negative breast cancer eligible for treatment with pembrolizumab.

The newest indication is the first approval of pembrolizumab for breast cancer, according to Merck.